top of page
JTC_VI_Webcast_OTLK.png

Outlook Therapeutics discusses its recently received European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD

Access, Ideas, Clarity

A leading virtual platform providing investors with direct access to innovative companies, management teams and thought leaders

Contat Us
bottom of page